SILVERARC CAPITAL MANAGEMENT, LLC

Position in ERAS — Erasca, Inc.

CIK 1816307 BOSTON, MA

Position in ERAS

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$23,138,636

-$6,823,682 QoQ

Shares Held

1,263,026

-31.8% QoQ

Ownership

0.361%

of shares outstanding

% of Portfolio

2.58%

of 13F equity value

Holder Rank

#40

of 257 holders

Holding Since

Sep 2021

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. ERAS ranks #13 (2.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	206,234	$55,006,732
2	CELC	Celcuity Inc.	500,996	$52,414,201
3	COGT	Cogent Biosciences, Inc.	1,280,707	$49,563,360
4	URGN	UroGen Pharma Ltd.	1,301,979	$47,912,827
5	IMNM	Immunome Inc.	2,017,009	$42,740,420
6	DNTH	Dianthus Therapeutics, Inc. /DE/	390,000	$38,017,200
7	RYTM	Rhythm Pharmaceuticals, Inc.	311,461	$34,581,514
8	ORKA	Oruka Therapeutics, Inc.	352,802	$33,576,166

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$23,138,636	1,263,026	-31.8%	Shares	Sole	2026-08-13
2026-03-31	$29,962,318	1,851,812	+40.5%	Shares	Sole	2026-05-14
2025-12-31	$4,901,412	1,317,584	-3.7%	Shares	Sole	2026-02-12
2025-09-30	$2,982,403	1,368,075	-46.8%	Shares	Sole	2025-11-12
2025-06-30	$3,263,380	2,569,591	-65.1%	Shares	Sole	2025-08-14
2025-03-31	$10,094,154	7,367,996	-2.3%	Shares	Sole	2025-05-14
2024-12-31	$18,935,191	7,543,901	+8.6%	Shares	Sole	2025-02-14
2024-09-30	$18,963,912	6,946,488	-11.1%	Shares	Sole	2024-11-14
2024-06-30	$18,447,945	7,816,926	+3392.1%	Shares	Sole	2024-08-14
2024-03-31	$461,120	223,845	+140.4%	Shares	Sole	2024-05-15
2021-09-30	$1,976,048	93,122	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.